MAX-40279 hemifumarate free base

MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase.

For research use only. Not for human or veterinary use.

Target FLT3 FGFR

Research area Inflammation/Immunology Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

MAX-40279 hemifumarate structure

CAS No.: 2388506-43-0

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 650.00	BP-02269-25mg	In stock	Get quote
50 mg	USD 900.00	BP-02269-50mg	In stock	Get quote
100 mg	USD 1,300.00	BP-02269-100mg	In stock	Get quote
250 mg	USD 2,300.00	BP-02269-250mg	In stock	Get quote
500 mg	Inquire	BP-02269-500mg	In stock	Inquire
1 g	Inquire	BP-02269-1g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).

Biological activity

MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.

Identifiers

SMILES: CC1=C(C2=NC(=NC=C2S1)NC3=CN(N=C3)C4CCNCC4)C5=C(C=C(C=C5)F)OC.CC1=C(C2=NC(=NC=C2S1)NC3=CN(N=C3)C4CCNCC4)C5=C(C=C(C=C5)F)OC.C(=C/C(=O)O)\C(=O)O
InChIKey: BCHMKHOVSSCBHQ-WXXKFALUSA-N

Specifications

MW (average): 993.1140
Formula: C₄₈H₅₀F₂N₁₂O₆S₂
CAS No.: 2388506-43-0
Physical state: Solid
Color: Off-white to light yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃, 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMF

In vitro: DMF : 1.96 mg/mL

Documents

References

[1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1.

[2]. Yuguang Wang, et al. Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, Blood, Volume 132, Supplement 1, 2018.

[3]. Xue Z, et al. PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis. Theranostics. 2025 Jan 1;15(2):745-765.

Same target

Search FLT3

Same research area

Search Inflammation/Immunology